Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alexion Pharmaceuticals : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Excessive-pricing Case

10/11/2021 | 08:09am EST

The Attorney General of Canada has sought leave to appeal to the Supreme Court in an excessive-pricing case regarding the drug SOLIRIS.

As we reported, Alexion Pharmaceuticals Inc. was successful before the Federal Court of Appeal in an application for judicial review of a 2017 PMPRB decision finding that Alexion had sold SOLIRIS at an excessive price in Canada. The Federal Court of Appeal held that the Board decision was unreasonable and remitted the matter for reconsideration by the PMPRB.


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Kristin Wall
Norton Rose Fulbright Canada LLP
222 Bay Street, Suite 3000
P.O. Box 53
Toronto
Ontario
CANADA
Tel: 4162164000
Fax: 4162163930
E-mail: kevin.shea@nortonrosefulbright.com
URL: www.nortonrosefulbright.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about ALEXION PHARMACEUTICALS, INC.
01/10AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurim..
CI
2021M&A market remains strong despite decline in activity
AQ
2021LIFE SCIENCES : Vavilov And The New Regulatory Environment
AQ
2021ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces..
AQ
2021Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in ..
CI
2021OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president..
AQ
2021AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development ..
CI
2021Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Bios..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float -
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Income Statement Evolution
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors